Stockscreener 앱 받기
14.36
4.97%
0.68
시간 외 거래:
14.29
-0.07
-0.49%
전일 마감가:
$13.68
열려 있는:
$13.865
하루 거래량:
14.86M
Relative Volume:
1.69
시가총액:
$16.54B
수익:
$14.33B
순이익/손실:
$-3.79B
주가수익비율:
-4.53
EPS:
-3.17
순현금흐름:
$1.84B
1주 성능:
+10.72%
1개월 성능:
+15.25%
6개월 성능:
+60.63%
1년 성능:
+31.86%
1일 변동 폭
$13.82
$14.49
1주일 범위
$12.92
$14.49
52주 변동 폭
$6.85
$14.49
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
VTRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
14.36 | 15.76B | 14.33B | -3.79B | 1.84B | -3.17 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.74 | 55.06B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.70 | 53.95B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
10.78 | 46.71B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.96 | 41.68B | 17.41B | 1.43B | 774.28M | 1.219 |
|
UTHR
United Therapeutics Corp
|
482.59 | 20.59B | 3.13B | 1.27B | 1.12B | 26.39 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-16 | 업그레이드 | Argus | Hold → Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Viatris Inc (VTRS) Stock Price Up 5.3% on Feb 4 - GuruFocus
Viatris Announces Chief Legal Officer Transition and Successor - TipRanks
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026 - The AI Journal
Viatris Appoints Matthew J. Maletta as Chief Legal Officer - Viatris
What are Wall Street analysts' target price for Viatris stock? - MSN
Viatris stock hits 52-week high at $13.49 By Investing.com - Investing.com Nigeria
Viatris stock hits 52-week high at $13.49 - Investing.com
Palmetto Grain Brokerage - Palmetto Grain Brokerage
What Are Wall Street Analysts' Target Price for Viatris Stock? - Yahoo Finance
What Does the Market Think About Viatris Inc? - Benzinga
Piper Sandler raises Viatris stock price target to $12 on brand strength - Investing.com UK
Piper Sandler raises Viatris stock price target to $12 on brand strength By Investing.com - Investing.com Nigeria
Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight - GlobeNewswire Inc.
Viatris launches ‘EmpowerED for Life’ for men’s health in Africa - MSN
Should Viatris’ (VTRS) First Inpefa UAE Launch Shape Investor Views on Its Innovation Strategy? - simplywall.st
Understanding the Setup: (VTRS) and Scalable Risk - Stock Traders Daily
Will Viatris Inc benefit from green energy policiesPortfolio Value Report & Free Verified High Yield Trade Plans - baoquankhu1.vn
Viatris Launches Inpefa In UAE As Valuation And Growth Draw Focus - Sahm
Is Viatris (VTRS) Pricing Reflect Its Recent Multi‑Year Share Price Recovery - Yahoo Finance
Viatris (VTRS) Valuation Check After First International Inpefa Heart Failure Launch - Yahoo Finance
Viatris Earnings Preview: What to Expect - Barchart.com
Viatris launches heart failure drug Inpefa in UAE, first outside US - Investing.com Nigeria
Viatris launches heart failure drug Inpefa in UAE, first outside US By Investing.com - Investing.com South Africa
3 Reasons to Sell VTRS and 1 Stock to Buy Instead - Finviz
Viatris Inc. Stock Outperforms Market Despite Losses On The Day - 富途牛牛
Viatris Launches Inpefa in United Arab Emirates - marketscreener.com
Viatris Launches Inpefa To Treat Heart Failure In UAE - Nasdaq
Viatris Launches Inpefa, Expanding Its Heart Failure Portfolio And Broadening Presence In Cardiovascular Diseases - TradingView — Track All Markets
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure - Sahm
Movement Recap: Is Viatris Inc backed by strong institutional buyingBear Alert & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Biocon Raises Rs 4.15 Billion Via QIP For Biologics Buy - Construction World India
Levels Update: Will Viatris Inc stock hit new highs in YEARJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
Argus Research Upgrades Viatris (VTRS) - Nasdaq
Biocon Secures Rs 4,150 Cr Through QIP to Buy Out Viatris Stake in Biologics Arm - Medical Dialogues
Viatris stock tests multi-year ceiling after impressive rally - FXStreet
United States Treatment-Resistant Depression Market to grow - openPR.com
Cash offers target up to $450M of Viatris 2026 and 2025 notes - Stock Titan
Viatris (VTRS) Gets a Sell from Bank of America Securities - The Globe and Mail
Biocon Raises Rs 4,150 Cr via QIP Issue - Rediff MoneyWiz
RSI Check: Is Viatris Inc. impacted by rising ratesWeekly Profit Summary & Daily Profit Focused Screening - baoquankhu1.vn
Contact UsCeres CourierViatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation - FinancialContent
Viatris stock steadies in premarket after a 5% jump on JPM conference remarks — what investors watch next - TechStock²
Generic Drugs Market to Hit US$ 942.69 Billion by 2033 | CAGR 7.1% | - openPR.com
Viatris Inc. stock rises Tuesday, outperforms market - MSN
What is the earnings history of Viatris IncWeekly Investment Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
Viatris Stock: Is Wall Street Bullish or Bearish? - MSN
Viatris hits main goals in Phase 3 trial for birth control patch - MSN
Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims - Law360
Viatris Inc. Stock Rises Friday, Outperforms Market - 富途牛牛
Why Analysts See The Viatris (VTRS) Story Shifting With Affordable Medicines And A US$16 Target - Yahoo Finance
Viatris Inc.: Can a Hybrid Pharma Powerhouse Reinvent the Generic Drug Game? - AD HOC NEWS
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.25%
0.90%
자본화:
|
볼륨(24시간):